TY - JOUR
T1 - In vitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation
AU - Snyder, E. L.
AU - Baril, L.
AU - Cooper, D. L.
AU - Min, K.
AU - Mechanic, S.
AU - Stoddart, L.
AU - Burtness, B.
AU - Seagraves, P.
AU - Debelak, J.
AU - Gudino, M.
AU - McCullough, J.
PY - 2000
Y1 - 2000
N2 - BACKGROUND: A clinical study was performed to evaluate the peripheral blood progenitor cell (PBPC) collection, transfusion, and engraftment characteristics associated with use of a blood cell separator (Amicus, Baxter Healthcare). STUDY DESIGN AND METHODS: Oncology patients (n = 31) scheduled for an autologous PBPC transplant following myeloablative therapy were studied. PBPCs were mobilized by a variety of chemotherapeutic regimens and the use of G-CSF. As no prior studies evaluated whether PBPCs collected on the Amicus separator would be viable after transfusion, to ensure patient safety, PBPCs were first collected on another cell separator (CS-3000 Plus, Baxter) and stored as backup. The day after the CS-3000 Plus collections were completed, PBPC collections intended for transfusion were performed using the Amicus instrument. For each transplant, >2.5 x 106 CD34+ PBPCs per kg of body weight were transfused. RESULTS: Clinical data collected on the donors immediately before and after PBPC collection with the Amicus device were comparable to donor data similarly obtained for the CS-3000 Plus collections. While the number of CD34+ cells and the RBC volume in the collected products were equivalent for the two devices, the platelet content of the Amicus collections was significantly lower than that of the CS-3000 Plus collections (4.35 x 1010 platelets/ bag vs. 6.61 x 1010 platelets/bag, p<0.05). Collection efficiencies for CD34+ cells were 64 ± 23 percent for the Amicus device and 43 ± 14 percent for the CS-3000 Plus device (p<0.05). The mean time to engraftment for cells collected via the Amicus device was 8.7 ± 0.7 days for >500 PMNs per μL and 9.7 ± 1.5 days to attain a platelet count of >20,000 per μL - equivalent to data in the literature. No CS-3000 Plus backup cells were transfused and no serious adverse events attributable to the Amicus device were encountered. CONCLUSIONS: The mean Amicus CD34+ cell collection efficiency was better (p<0.05) than that of the CS-3000 Plus collection. Short-term engraftment was durable. The PBPCs collected with the Amicus separator are safe and effective for use for autologous transplant patients requiring PBPC rescue from high-dose myeloablative chemotherapy.
AB - BACKGROUND: A clinical study was performed to evaluate the peripheral blood progenitor cell (PBPC) collection, transfusion, and engraftment characteristics associated with use of a blood cell separator (Amicus, Baxter Healthcare). STUDY DESIGN AND METHODS: Oncology patients (n = 31) scheduled for an autologous PBPC transplant following myeloablative therapy were studied. PBPCs were mobilized by a variety of chemotherapeutic regimens and the use of G-CSF. As no prior studies evaluated whether PBPCs collected on the Amicus separator would be viable after transfusion, to ensure patient safety, PBPCs were first collected on another cell separator (CS-3000 Plus, Baxter) and stored as backup. The day after the CS-3000 Plus collections were completed, PBPC collections intended for transfusion were performed using the Amicus instrument. For each transplant, >2.5 x 106 CD34+ PBPCs per kg of body weight were transfused. RESULTS: Clinical data collected on the donors immediately before and after PBPC collection with the Amicus device were comparable to donor data similarly obtained for the CS-3000 Plus collections. While the number of CD34+ cells and the RBC volume in the collected products were equivalent for the two devices, the platelet content of the Amicus collections was significantly lower than that of the CS-3000 Plus collections (4.35 x 1010 platelets/ bag vs. 6.61 x 1010 platelets/bag, p<0.05). Collection efficiencies for CD34+ cells were 64 ± 23 percent for the Amicus device and 43 ± 14 percent for the CS-3000 Plus device (p<0.05). The mean time to engraftment for cells collected via the Amicus device was 8.7 ± 0.7 days for >500 PMNs per μL and 9.7 ± 1.5 days to attain a platelet count of >20,000 per μL - equivalent to data in the literature. No CS-3000 Plus backup cells were transfused and no serious adverse events attributable to the Amicus device were encountered. CONCLUSIONS: The mean Amicus CD34+ cell collection efficiency was better (p<0.05) than that of the CS-3000 Plus collection. Short-term engraftment was durable. The PBPCs collected with the Amicus separator are safe and effective for use for autologous transplant patients requiring PBPC rescue from high-dose myeloablative chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0033839381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033839381&partnerID=8YFLogxK
U2 - 10.1046/j.1537-2995.2000.40080961.x
DO - 10.1046/j.1537-2995.2000.40080961.x
M3 - Article
C2 - 10960524
AN - SCOPUS:0033839381
VL - 40
SP - 961
EP - 967
JO - Transfusion
JF - Transfusion
SN - 0041-1132
IS - 8
ER -